Life
Implications of ‘Most Favored Nation’ Drug Pricing Model for Pharmaceutical Infrastructure
The proposed 'Most Favored Nation' pricing model for pharmaceuticals could significantly impact drug pricing structures and access in the U.S. healthcare system.
Editorial Staff
1 min read
The 'Most Favored Nation' (MFN) pricing model aims to align U.S. drug prices with those in other countries, potentially addressing the rising costs of pharmaceuticals.
This model could enhance affordability and access to medications, thereby influencing healthcare delivery and operational frameworks within the pharmaceutical sector.
As outlined in Health Affairs, the MFN approach may necessitate adjustments in pricing strategies and supply chain management to accommodate new pricing standards.